FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2082662617> ?p ?o ?g. }

• W2082662617 endingPage "125" @default.
• W2082662617 startingPage "117" @default.
• W2082662617 abstract "The aim of this article was first to review the complex pathophysiological mechanisms responsible for symptoms and signs of primary chronic venous disease (CVD) that allow the identification of targets for pharmacological treatment. The results of CVD treatment with venoactive drugs (VADs) were emphasised and presented in the form of recommendations. The last section raises key questions to be answered to improve protocols for good clinical trials and to draw up future guidelines on these agents.The literature has been reviewed here using PubMed and Embase.Venous hypertension appears to underlie all clinical manifestations of primary CVD. Inflammation is key in wall remodelling, valve failure and subsequent venous hypertension. Changes in the haemodynamics of veins are transmitted to the microcirculation, resulting in capillary alteration leading to oedema, skin changes and eventually venous ulceration. Venous symptoms may be the result of interplays between pro-inflammatory mediators and nerve fibres located in the venous wall. Therefore, venous inflammation constitutes a promising therapeutic target for pharmacological intervention, and some available VADs could attenuate various elements of venous inflammation. Based on recent studies, reviews and guidelines, tentative recommendations for the use of VADs were proposed and strong recommendations were given to two of them (micronised purified flavonoid fraction and oxerutins).VADs should be accorded a better role in the management of CVD. However, larger and more definitive clinical trials are needed to improve the existing recommendations." @default.
• W2082662617 created "2016-06-24" @default.
• W2082662617 creator A5048127329 @default.
• W2082662617 creator A5051719603 @default.
• W2082662617 date "2011-01-01" @default.
• W2082662617 modified "2023-10-16" @default.
• W2082662617 title "Pharmacological Treatment of Primary Chronic Venous Disease: Rationale, Results and Unanswered Questions" @default.
• W2082662617 cites W1970925332 @default.
• W2082662617 cites W1979930765 @default.
• W2082662617 cites W1991475780 @default.
• W2082662617 cites W1992585421 @default.
• W2082662617 cites W2000841294 @default.
• W2082662617 cites W2007425159 @default.
• W2082662617 cites W2011859830 @default.
• W2082662617 cites W2015291456 @default.
• W2082662617 cites W2021319806 @default.
• W2082662617 cites W2022808176 @default.
• W2082662617 cites W2023526357 @default.
• W2082662617 cites W2032541700 @default.
• W2082662617 cites W2042195357 @default.
• W2082662617 cites W2042655036 @default.
• W2082662617 cites W2043916979 @default.
• W2082662617 cites W2051142066 @default.
• W2082662617 cites W2054552132 @default.
• W2082662617 cites W2060321368 @default.
• W2082662617 cites W2068131497 @default.
• W2082662617 cites W2069559840 @default.
• W2082662617 cites W2079065919 @default.
• W2082662617 cites W2084753040 @default.
• W2082662617 cites W2086137808 @default.
• W2082662617 cites W2099404042 @default.
• W2082662617 cites W2102581021 @default.
• W2082662617 cites W2104431019 @default.
• W2082662617 cites W2121431731 @default.
• W2082662617 cites W2123203888 @default.
• W2082662617 cites W2129397054 @default.
• W2082662617 cites W2130611882 @default.
• W2082662617 cites W2140363580 @default.
• W2082662617 cites W2141486920 @default.
• W2082662617 cites W2143386240 @default.
• W2082662617 cites W2312326997 @default.
• W2082662617 cites W2985326512 @default.
• W2082662617 cites W4211164407 @default.
• W2082662617 cites W4243816333 @default.
• W2082662617 cites W4250344409 @default.
• W2082662617 cites W4295715489 @default.
• W2082662617 cites W4320301267 @default.
• W2082662617 doi "https://doi.org/10.1016/j.ejvs.2010.09.025" @default.
• W2082662617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21126890" @default.
• W2082662617 hasPublicationYear "2011" @default.
• W2082662617 type Work @default.
• W2082662617 sameAs 2082662617 @default.
• W2082662617 citedByCount "98" @default.
• W2082662617 countsByYear W20826626172012 @default.
• W2082662617 countsByYear W20826626172013 @default.
• W2082662617 countsByYear W20826626172014 @default.
• W2082662617 countsByYear W20826626172015 @default.
• W2082662617 countsByYear W20826626172016 @default.
• W2082662617 countsByYear W20826626172017 @default.
• W2082662617 countsByYear W20826626172018 @default.
• W2082662617 countsByYear W20826626172019 @default.
• W2082662617 countsByYear W20826626172020 @default.
• W2082662617 countsByYear W20826626172021 @default.
• W2082662617 countsByYear W20826626172022 @default.
• W2082662617 countsByYear W20826626172023 @default.
• W2082662617 crossrefType "journal-article" @default.
• W2082662617 hasAuthorship W2082662617A5048127329 @default.
• W2082662617 hasAuthorship W2082662617A5051719603 @default.
• W2082662617 hasBestOaLocation W20826626171 @default.
• W2082662617 hasConcept C10162356 @default.
• W2082662617 hasConcept C126322002 @default.
• W2082662617 hasConcept C12722491 @default.
• W2082662617 hasConcept C164705383 @default.
• W2082662617 hasConcept C177713679 @default.
• W2082662617 hasConcept C178853913 @default.
• W2082662617 hasConcept C2776106345 @default.
• W2082662617 hasConcept C2776914184 @default.
• W2082662617 hasConcept C2777202286 @default.
• W2082662617 hasConcept C2779134260 @default.
• W2082662617 hasConcept C2909418356 @default.
• W2082662617 hasConcept C535046627 @default.
• W2082662617 hasConcept C60644358 @default.
• W2082662617 hasConcept C71924100 @default.
• W2082662617 hasConcept C86803240 @default.
• W2082662617 hasConceptScore W2082662617C10162356 @default.
• W2082662617 hasConceptScore W2082662617C126322002 @default.
• W2082662617 hasConceptScore W2082662617C12722491 @default.
• W2082662617 hasConceptScore W2082662617C164705383 @default.
• W2082662617 hasConceptScore W2082662617C177713679 @default.
• W2082662617 hasConceptScore W2082662617C178853913 @default.
• W2082662617 hasConceptScore W2082662617C2776106345 @default.
• W2082662617 hasConceptScore W2082662617C2776914184 @default.
• W2082662617 hasConceptScore W2082662617C2777202286 @default.
• W2082662617 hasConceptScore W2082662617C2779134260 @default.
• W2082662617 hasConceptScore W2082662617C2909418356 @default.
• W2082662617 hasConceptScore W2082662617C535046627 @default.
• W2082662617 hasConceptScore W2082662617C60644358 @default.
• W2082662617 hasConceptScore W2082662617C71924100 @default.

• next